Mifepristone Induction for Fetal Demise

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Intrauterine Fetal Demise, Fetal Death

In brief

Methods: Double blinded, randomized controlled trial with 1:1 allocation of mifepristone or placebo at initiation of induction of labor for fetal demise 20 weeks estimated gestational age or greater. Hypothesis: Mifepristone will expedite time to delivery of fetus among demise patients, when compared to placebo, and in conjunction with other pharmacologic methods for induction of labor. Expected outcomes: The addition of a progesterone receptor modulator will expedite time to delivery of the fetus and ultimately improve the experience associated with induction of labor for fetal demise.

Key facts

Study ID
NCT02620904
Run by
Montefiore Medical Center
People needed
9
Starts
2016-07-14
Expected to finish
2020-01-01
Last updated by the study team
2021-02-18

Who can join

Age: 16 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.